T Lymphoblastic Leukemia/Lymphoma — Trials

T Lymphoblastic Leukemia/Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

140 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 35
Ph III recruiting: 2
Growth YoY: —
Industry share: 12%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 48.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06738368	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia	suspended	Phase 2	30	University of WashingtonOTHER	1	Sep 29, 2026	clinicaltrials
NCT04828174	Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies	suspended	Phase 1	9	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine